Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.49 |
| ▸ | TOP1 | P11387 | 2/20 | 0.35 |
| ▸ | CYCS | P99999 | 2/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409322 | 0.80 | TERT (0.48) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL4753685 | 0.74 | TERT (0.53) | TERTTOP1CYCS | |
| SCHEMBL453031 | 0.73 | TERT (0.52) | TERTTOP1CYCSENPP2 | |
| SCHEMBL29935687 | 0.72 | TERT (0.51) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL1517324 | 0.68 | TERT (0.55) | TERTTOP1CYCSENPP2 | |
| SCHEMBL448020 | 0.68 | TERT (0.49) | TERTTOP1CYCSENPP2 | |
| SCHEMBL29869092 | 0.68 | TERT (0.49) | TERTTOP1CYCSENPP2 | |
| SCHEMBL450264 | 0.67 | TERT (0.48) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL1409803 | 0.66 | TERT (0.49) | TERTTOP1CYCSENPP2 | |
| SCHEMBL30207592 | 0.64 | TERT (0.63) | TERTTOP1CYCSENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289434-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | AEOLUS PHARMACEUTICALS INC. | 2015-08-20 | — | — | US | disclosed |
| US-8946202-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | Aeouls Sciences, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8546562-B2 | Substituted porphyrins | DUKE UNIVERSITY | 2013-10-01 | — | — | US | disclosed |
| US-20120214780-A1 | SUBSTITUTED PORPHYRINS | AEOLUS SCIENCES, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8217026-B2 | Substituted porphyrins | AEOLUS SCIENCES, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110065679-A1 | Substituted Porphyrins | AEOLUS PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2295435-A1 | Substituted porphyrins and their therapeutic use | National Jewish Health (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7820644-B2 | Substituted porphyrins | Aelous Pharmaceuticals, Inc. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2007-08-23 | — | — | US | disclosed |
| EP-1616869-A1 | Substituted porphyrins and their therapeutic use | National Jewish Medical and Research Center (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1155019-B1 | SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USE | NAT JEWISH MED & RES CENTER (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6544975-B1 | Mimetics that inhibit lipid peroxidation; for use in the treatment of diseases or disorders mediated by oxidative stress, such as asthma, inflammatory bowel disease, arthritis and vasculitis. | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214780-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885CYCS 76/4885 |
| US-20150231150-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885CYCS 76/4885 |
| US-20110065679-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885CYCS 76/4885 |
| US-20140011794-A1 | SUBSTITUTED PORPHYRINS | PPOX, GPX4, PRDX5 | TERT 821/4885TOP1 4291/4885CYCS 76/4885 |
| US-20070197496-A1 | for modulating cellular levels of oxidants such as superoxide radicals, hydrogen peroxide, peroxynitrite, lipid peroxides, hydroxyl radicals and thiyl radicals, treating diabetes mellitus Type I or Type II | GPX4, LPO, TXNRD2 | TERT 771/4885TOP1 3334/4885CYCS 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.